Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy
<p>Abstract</p> <p>Background</p> <p>Atomoxetine is FDA-approved as a treatment of attention-deficit/hyperactivity disorder (ADHD) in patients aged 6 years to adult. Among pediatric clinical trials of atomoxetine to date, six with a randomized, double-blind, placebo-con...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-09-01
|
| Series: | Child and Adolescent Psychiatry and Mental Health |
| Online Access: | http://www.capmh.com/content/2/1/25 |